Skip to main content
Erschienen in: BMC Medical Genetics 1/2019

Open Access 01.12.2019 | Case report

Case reports: novel TUBG1 mutations with milder neurodevelopmental presentations

verfasst von: Yue T. K. Yuen, Ilaria Guella, Elke Roland, Michael Sargent, Cyrus Boelman

Erschienen in: BMC Medical Genetics | Ausgabe 1/2019

Abstract

Background

Tubulinopathies result from mutations in tubulin genes, including TUBG1, responsible for cell microtubules, are characterized by brain development abnormalities, microcephaly, early-onset epilepsy, and motor impairment. Only eleven patients with TUBG1 mutations have been previously described in literature to our knowledge. Here we present two new patients with novel de novo TUBG1 mutations and review other cases in the literature.

Case presentations

Both patients have microcephaly and intellectual disability. Patient B further fits a more typical presentation, with well-controlled epilepsy and mild hypertonia, whereas Patient A’s presentation is much milder without these other features.

Conclusion

This report expands the spectrum of TUBG1 mutation manifestations, suggesting the possibility of less severe phenotypes for patients and families, and influencing genetic counselling strategies.
Abkürzungen
EEG
Electroencephalogram
MRI
Magnetic resonance imaging
SD
Standard deviation

Background

Mutations in the tubulin genes (e.g. TUBA1A, TUBB2A, TUBA8, TUBB2B, TUBB3, TUBB5, TUBG1) are associated with a range of brain malformations. Common tubulinopathic presentations include an array of lissencephalies, polymicrogyria-like cortical dysplasia, simplified gyral pattern, microlissencephaly, and a dysmorphic corpus callosum [1, 2]. Eleven patients with a TUBG1 mutation have been described in the literature to our knowledge, and only limited clinical information is available for these patients. They are described with microcephaly, motor impairment, intellectual disability and epilepsy [1, 3, 4]. Here we report two further patients with novel TUBG1 mutations and milder presentations.

Case presentations

These two patients are followed at BC Children’s Hospital, a public academic tertiary pediatric referral centre, serving a population of nearly 5 million people.
Patient A is a 10-year old right-handed female born following a pregnancy complicated by antenatal microcephaly noted on fetal ultrasound. She is of Chinese descent and has no family history of consanguinity or congenital anomalies. Her early development milestones were normal; she sat at 6 months, crawled at 8 months and walked at 12 months of age. Her mild intellectual disability was first apparent at the age of six years and she is now two years behind her peers academically, with no regression in development. She speaks two languages. She has an independent education plan. At birth her head circumference was not measured and by ten years of age the patient’s head circumference was 46 cm (2 SD below the mean). She has some dysmorphic facial features including prominent ears relative to her microcephaly, a tented mouth, and bilateral 5th finger clinodactyly. Neurological examination was otherwise unremarkable. Magnetic resonance imaging (MRI) at nine years of age revealed microcephaly, posteriorly predominant simplified cortical gyri, and areas of band and nodular heterotopia (Fig. 1). No seizure-like activity has been described by the parents but a screening electroencephalogram (EEG) demonstrated occasional interictal sharp waves over the right central temporal areas in drowsiness and sleep, suggestive of a predisposition towards focal onset seizures, in addition to occasional, non-specific, generalized paroxysmal delta activity in sleep. Chromosomal microarray and biochemical screening for inborn errors of metabolism (as described elsewhere) were both unremarkable [5]. Clinical whole exome sequencing (Centogene AG, Rostock, Germany) revealed a novel, de novo TUBG1 missense mutation (NM_001070.4: c.202G > A; p.Asp68Asn), using a trio approach (proband plus parents), chosen due to the multiple potential causative genes. The parents consented to this report.
Patient B is a 13-month old male born following a pregnancy complicated by fetal ultrasound findings of microcephaly (bitemporal narrowing), possible cavum septum pellucidum, enlarged ventricles, agenesis of the corpus callosum, and lissencephaly. He is of Caucasian descent with no family history of consanguinity or congenital anomalies, but a maternal history of simple febrile seizures and paternal history of asymptomatic Huntington’s disease gene carriers. Head circumference at birth was below the 3rd percentile, (measured as 21 cm at 2 weeks of age), length 10-50th percentile, and weight 10th percentile. Up-slanting palpebral fissures were noted. Within the first hour of life, he experienced a seizure characterized by left-sided clonic activity with secondary bilateral synchrony and oxygen desaturation. This was managed with phenobarbital. The interictal EEG at this point showed diffuse suppression and excessive left central sharp waves, suggestive of cerebral dysfunction with some focality. A full septic workup was completed and negative. MRI at the age of thirteen days demonstrated microcephaly, a small cerebellum, reduced number and complexity of the cerebral sulci and gyri with no cortical thickening or polymicrogyria, general paucity of cerebral white matter, dilated lateral ventricles, a normal third ventricle, small lentiform nuclei which were not well separated from the small thalami, and a grossly normal corpus callosum for age. There was normal myelination in the brainstem and cerebellum but there was lack of myelination in the posterior limbs of internal capsules. The patient had twenty-nine more seizures within the first forty-three days of life. These were twenty to forty seconds in length and generally associated with feeding. They involved a combination of apnea and cyanosis, lip smacking, head turning to the right, left eye deviation, arm flexion, leg extension, and post-ictal fatigue. At last follow-up, seizures were controlled with levetiracetam and topiramate. He has central hypothyroidism on thyroxine but otherwise normal pituitary function. He was also found to have small optic nerves, and a small secundum atrial septal defect shunting left to right. At 13 months, last follow up, he is not yet rolling or sitting independently, but has head control, brings his hands to the midline, is babbling and visually fixing and following. Neurological examination is notable for slightly low axial tone and increased appendicular tone, with a head circumference of 36 cm (below 3rd percentile). Chromosomal microarray and biochemical screening for inborn errors of metabolism were both unremarkable [5]. Clinical whole exome sequencing (GeneDx, Gaitherburg, USA) revealed a novel, de novo TUBG1 missense mutation (NM_001070.4: c1021C > T; p.Arg341Trp) using a trio approach. The parents consented to this report.

Discussion and conclusions

Tubulinopathies are characterized by a wide range of brain malformations, including lissencephaly, polymicrogyria and mildly simplified gyral patterning. The full phenotypic spectrum of tubulinopathies is however not yet fully known. All but one of the eleven reviewed cases of TUBG1 mutations involved epilepsy, majority of which were refractory and early-onset in nature. Of the seven patients with birth head circumference measurements, six had microcephaly (< 2 standard deviations (SD) below the mean) and four of the six had severe microcephaly (< 3 SD below the mean). Motor dysfunction was present in all but one patient out of the nine with the available data, ranging from delayed motor development to spastic tetraplegia. All patients suffered from intellectual disability ranging from moderate to severe [1, 3, 4].
Patient A represents the least severe manifestation of TUBG1 mutation reported so far, having microcephaly, brain malformations, mild facial dysmorphia, and mild intellectual disability, but no motor impairment or epilepsy. Patient B had a more typical presentation sharing features with the more severe phenotype: microcephaly, brain malformations, global development delay and early-onset epilepsy (though easily controlled). Other neurological, clinical, and genetic phenotypes are compared in summary in Table 1.
Table 1
Clinical, imaging, and genetic features of patients with TUBG1 mutations
ID
Patient A
Patient B
Patient 11,3
Patient 21,3
Patient 31,3
Patient 44
Patient 54
Patient 64
Patient 74
Patient 84
Patient 94
Patient 104
Patient 114
Mutation
c.202G > A; p.Asp68Asn
c1021C > T; p.Arg341Trp
c.1160 T > C; p.Leu387Pro
c.275A > G; p.Tyr92Cys
c.991A > C; p.Thr331Pro
c.63C > A; p.Phe21Leu
c.985G > T; p.Asp329Tyr
c.776C > T; p.Ser259Leu
c.776C > T; p.Ser259Leu
c.776C > T; p.Ser259Leu
c.776C > T; p.Ser259Leu
c.769A > T; p.Ile257Phe
c.776C > T; p.Ser259Leu
Mode of inheritance
De novo
De novo
De novo
De novo
Father’s DNA N/A
De novo
Father’s DNA N/A
De novo
De novo
Germline mosaicism in parent
Germline mosaicism in parent
De novo
De novo
Mutation effect
Aspartate to asparagine within a highly conserved residue in the GTP-binding pocket
Arginine to tryptophan within a highly conserved residue located in the C-terminal domain that is required for the dimerization of y-tubulin
Leucine to proline within a highly conserved residue within an α-helix located in the C-terminal domain
Tyrosine to cysteine within a highly conserved residue in the vicinity of the GTPase domain
Threonine to proline within a highly conserved residue in an α-helix within the γ-γ protein interaction domain located in the C-terminal domain
Phenylalanine to leucine within the GTPase domain
Aspartate to tyrosine within a highly conserved residue in the C-terminal domain. Located on the surface of the TUBG1 protein
Serine to leucine within a highly conserved residue located in the C-terminal domain
Serine to leucine within a highly conserved residue located in the C-terminal domain
Serine to leucine within a highly conserved residue located in the C-terminal domain
Serine to leucine within a highly conserved residue located in the C-terminal domain
Isoleucine to phenylalanine within a highly conserved residue located in the C-terminal domain
Serine to leucine within a highly conserved residue located in the C-terminal domain
Sex
F
M
F
M
F
M
M
F
F
F
M
M
F
Age at follow-up
10y
6mo
21y
18mo
31y
33y
21y
19mo
14y
11y 6mo
9y 6mo
15y
18mo
Head circumference
<−2.1 SD
<−1.9 SD
<−5.5 SD
<−4 SD
<−1 SD
57 cm
53.1 cm (<−2.6 SD)
<−3.5 SD
N/A
47.5 cm at 6y 6mo (<−3.3 SD)
N/A
51.3 cm at 13y (<− 2.5 SD)
N/A
Epileptic
No
Yes
Yes
Yes
Yes
Yes
Yes
No
Yes
Yes
Yes
Yes
Yes
Seizure age of onset
< 1 h of life
Early-onset
N/A
Early-onset
36mo
N/A
6mo
4mo
N/A
3y 11mo
5mo
Type of seizures
Focal with secondary bilateral synchrony
N/A
Infantile spasms
N/A
Tonic-atonic-myoclonic
Partial complex; versive, myoclonic
Tonic-clonic
Generalized tonic-clonic
N/A
N/A
Focal, versive
Refractory epilepsy
No
Yes
Yes
Yes
N/A
Yes
N/A
N/A
N/A
N/A
No
Motor dysfunction
No
Mild axial hypotonia; appendicular hypertonia
Spastic tetraplegia (bedridden)
Spastic tetraplegia (bedridden)
Moderate cerebral palsy
Spastic tetraplegia (walks with support)
Spastic tetraplegia
Delayed motor development
Unsteady gait
Spastic diplegia
N/A
N/A
Delayed motor development
ID
Moderate
Moderate global delay
Severe
Severe
Moderate
Severe
Severe
N/A
N/A
Moderate
Moderate
Moderate (FS IQ-score 44)
Severe
Speech and Language Development
Normal
Moderate global delay
N/A
N/A
N/A
Only sounds, no speech
Non-verbal
Delayed
Non-verbal
50 words
Non-verbal
5–6 word sentences
Non-verbal
Age at MRI
9y
13 days
N/A
N/A
N/A
36y
11y
1y 6mo
12mo
13y 7mo
2mo
6y
9y
Cortical dysgenesis (MRI)
Posterior predominant pachygyria, band heterotopia, nodular heterotopia
Reduced cortical sulci and gyri
Severe posterior predominant pachygyria/agyria (posterior agyria, frontal pachygyria), thick cortex
Severe posterior predominant pachygyria/agyria (posterior agyria, frontal pachygyria), thick cortex
Posterior pachygyria, moderate posterior subcortical band heterotopia
Posterior predominant pachygyria (posterior frontal lobe and parieto-occipital cortex)
Diffuse agyria
Posterior predominant pachygyria (mild over frontal lobes, moderate over posterior lobes), cortex 10-13 mm thick
Posterior predominant pachygyria, sparse cells over occipital lobes, cortex 13-15 mm thick
Posterior predominant pachygyria (mild over frontal lobe, moderate over temporal and occipital lobes), cortex 6-13 mm thick
Posterior predominant pachygyria (mild over frontal lobe, moderate over temporal and occipital lobes), cortex > 15 mm thick
Posterior predominant pachygyria (almost normal over frontal lobes, pachygyria over perisylvian and occipital lobes), cortex 6-10 mm thick
Posterior predominant pachygyria (mild over frontal lobe, moderate over temporal and occipital lobe, deep parietal lobe infolding)
Corpus callosum (MRI)
Normal-Thick
Normal
Thin
Thick, dysmorphic
Thick, dysmorphic
Normal
Thin
Normal
Normal
Normal
Thin
Normal
Thin
Other MRI Findings
General paucity of white matter, small cerebellum, dilated lateral ventricles, small lentiform nuclei, small thalami, posterior limbs of internal capsule lacking myelination
Mildly enlarged lateral ventricles, mildly reduced white matter
Mildly enlarged lateral ventricles, severely reduced white matter
Enlarged perivascular spaces, enlarged posterior horns of lateral ventricles, hippocampal malrotation
Severely enlarged lateral ventricles, severely reduced white matter, dysplastic basal ganglia, hypoplastic brainstem, hypoplastic vermis
Mildly enlarged lateral ventricles, mildly reduced white matter
Mildly enlarged lateral ventricles, mildly reduced white matter
Enlarged posterior horns of lateral ventricles
Mildly enlarged lateral ventricles
Mildly enlarged posterior horns of lateral ventricles, mildly reduced white matter
Mildly enlarged lateral ventricles, mildly reduced white matter, dysplastic basal ganglia
F female, M male, y years, mo months, SD standard deviation, ID intellectual disability, − absent, N/A not available
Whereas tubulin gene mutations often follow an autosomal dominant mode of inheritance [2], TUBG1 mutations are almost entirely de novo [1, 3, 4]. Furthermore, tubulinopathies encompass a range of phenotypes including extreme lissencephaly, severe cerebellar hypoplasia, and varying cortical thickness [6, 7]. Despite overlap between the brain phenotypes of different tubulinopathies, certain phenotypes are associated with specific tubulin genes [8]. TUBG1 patients, are characterized by pachygyria/agyria that is most intense in the parieto-occipital regions with a posterior to anterior gradient as well as enlarged lateral ventricles and reduced white matter volume [3, 4]. Lastly, unlike other tubulinopathies, majority of TUBG1 mutation patients have a normal cerebellum, basal ganglia, and brainstem [1, 4]. Patient A coincides with the known TUBG1 presentation involving posteriorly-predominant pachygyria and a normal cerebellum, basal ganglia, and brainstem. However, this patient diverges from the known TUBG1 mutation phenotype due to the presence of band and nodular heterotopia, normal white matter volume, and normal lateral ventricle size. Patient B is similar to known TUBG1 mutation in having pachygyria (although not posteriorly-predominant), dilated lateral ventricles, reduced white matter, normal cerebellum, and brainstem. Unlike typical TUBG1 mutation phenotype, this patient has a small cerebellum. In consideration of the microcephaly spectrum, radiologically, Patent B may correspond to a label of congenital microcephaly with a simplified gyral pattern [9].
TUBG1 encodes for γ-tubulin, highly expressed in the developing fetal brain as a component of centrosomes. It plays an integral role in microtubule nucleation, thereby affecting microtubule-dependent mitosis and brain development [3, 4]. Poirier et al. introduced mutations in the γ-tubulin gene (tub4) in S. cerevisiae which interfered with microtubule nucleation. Suppression of TUBG1 in utero of mice also arrested neuronal migration [3]. Depending on the mutation locus, the different TUBG1 mutations are thought to have an effect on γ-tubulin structure or function. It is suspected that TUBG1 mutations affect neuronal migration hence MRI findings showing pachygyria/agyria. This is in comparison to other tubulinopathies which are more associated with polymicrogyria or dysgyria [4].
We suspect the TUBG1 mutations found to be likely pathogenic. Both missense mutations described in this paper were de-novo resulting in substitutions in highly conserved amino acids which are predicted to be damaging by multiple in-silico algorithms, including SIFT, PolyPhen-2, MutationTaster2. Neither mutation has been reported in public databases (gnomAD Browser), and two likely pathogenic entries are present in ClinVar for the Arg341 residue (Patient B). The p.Asp68Asn mutation (Patient A) affects a highly conserved residue in all 20 human tubulin proteins and their ancestral homologs. The Asp68 residue is located in the GTP-binding pocket and together with the Glu72 coordinates the Mg2+ ion that interacts with the GTP γ-phosphate [10, 11] (Fig. 2). The p.Arg341Trp mutation (Patient B) substitutes a positively-charged arginine with an aromatic amino-acid, within the Tubulin/FtsZ 2-layer sandwich (or C-terminal) domain (Fig. 2). The Arg341 residue is part of a stretch of polar amino acids (Arg339, Arg341, Glu342, Arg343 and Lys344) at the interface of γ–γ tubulin dimer and plays a critical role in the in assembly of the γ tubulin homodimer by forming multiple H-bonds with residue Asp252 on the opposite chain [12].
We present here two patients each with a novel, de novo TUBG1 mutation with common features of microcephaly and intellectual disability but lacking both spastic tetraplegia and more severe refractory epilepsy. The especially mild phenotype of patient A expands the spectrum associated with TUBG1 mutations and will provide a much different perspective in genetic counselling to families moving forward. However, further work is needed to more fully understand genotype-phenotype correlations in this rare genetic disorder.

Acknowledgements

The authors wish to thank Dr. Alexandra Faber, Ms. Lynne Beszant and Ms. Anna Castillo for their support in evaluating these children.

Funding

All funding for clinical testing was through the British Columbia Ministry of Health. Authors’ salaries are provided through the University of British Columbia (YY, IG, ER, MS) and its Summer Student Research Internship program (YY), and the Provincial Health Services Authority (ER, MS, CB). The funding body played no role in the design of the study, collection, analysis, and interpretation of data or in writing the manuscript.

Availability of data and materials

Data sharing is not applicable to this article as no datasets were generated or analysed during the current study. Due to personally identifying information on genetic, imaging and clinical reports, these cannot be made available in a public database; however, de-identified copies may be available for review through contacting the corresponding author.
Informed consent to participate in this study was obtained from the parents/legal guardians of the two children (under 16) reported in this study. This study was approved under the guidelines of the BC Children’s and Women’s Research Ethics Board.
Although no personally identifiable information is presented in this study, written informed consent for publication was obtained from the parents/legal guardians of the two children (under 18) reported in this study.

Competing interests

The authors of this manuscript have no financial or non-financial competing interests to declare.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://​creativecommons.​org/​licenses/​by/​4.​0/​), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://​creativecommons.​org/​publicdomain/​zero/​1.​0/​) applies to the data made available in this article, unless otherwise stated.
Literatur
5.
Zurück zum Zitat van Karnebeek CDM, Stockler-Ipsiroglu S. Early identification of treatable inborn errors of metabolism in children with intellectual disability: the treatable intellectual disability endeavor protocol in British Columbia. Paediatric Child Health. 2014;19(9):469–71.CrossRef van Karnebeek CDM, Stockler-Ipsiroglu S. Early identification of treatable inborn errors of metabolism in children with intellectual disability: the treatable intellectual disability endeavor protocol in British Columbia. Paediatric Child Health. 2014;19(9):469–71.CrossRef
Metadaten
Titel
Case reports: novel TUBG1 mutations with milder neurodevelopmental presentations
verfasst von
Yue T. K. Yuen
Ilaria Guella
Elke Roland
Michael Sargent
Cyrus Boelman
Publikationsdatum
01.12.2019
Verlag
BioMed Central
Erschienen in
BMC Medical Genetics / Ausgabe 1/2019
Elektronische ISSN: 1471-2350
DOI
https://doi.org/10.1186/s12881-019-0827-6

Weitere Artikel der Ausgabe 1/2019

BMC Medical Genetics 1/2019 Zur Ausgabe